IL264692A - - Google Patents
Info
- Publication number
- IL264692A IL264692A IL26469219A IL26469219A IL264692A IL 264692 A IL264692 A IL 264692A IL 26469219 A IL26469219 A IL 26469219A IL 26469219 A IL26469219 A IL 26469219A IL 264692 A IL264692 A IL 264692A
- Authority
- IL
- Israel
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E60/00—Enabling technologies; Technologies with a potential or indirect contribution to GHG emissions mitigation
- Y02E60/10—Energy storage using batteries
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20160101823 | 2016-08-10 | ||
| PCT/KR2017/008676 WO2018030806A1 (ko) | 2016-08-10 | 2017-08-10 | 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물 |
| KR1020170101594A KR102050463B1 (ko) | 2016-08-10 | 2017-08-10 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL264692A true IL264692A (cg-RX-API-DMAC7.html) | 2019-04-30 |
| IL264692B1 IL264692B1 (en) | 2025-08-01 |
| IL264692B2 IL264692B2 (en) | 2025-12-01 |
Family
ID=61524969
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL264692A IL264692B2 (en) | 2016-08-10 | 2019-02-06 | Heterodimeric cytokine fused to FC and pharmaceutical preparation containing the same |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US10696722B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP3511340B1 (cg-RX-API-DMAC7.html) |
| JP (3) | JP6993403B2 (cg-RX-API-DMAC7.html) |
| KR (4) | KR102050463B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN110267977A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017310163B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112019002394B1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3033475A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3511340T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3000558T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL264692B2 (cg-RX-API-DMAC7.html) |
| MX (2) | MX386014B (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201901071TA (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201900772B (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102050463B1 (ko) * | 2016-08-10 | 2019-11-29 | 아주대학교산학협력단 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물 |
| WO2019010224A1 (en) | 2017-07-03 | 2019-01-10 | Torque Therapeutics, Inc. | FUSION MOLECULES TARGETING IMMUNE REGULATORY CELLS AND USES THEREOF |
| EP3753631B1 (en) | 2018-02-14 | 2024-10-16 | Lg Chem, Ltd. | Catalyst loading method and method for preparation of butadiene by using same |
| CN110396133B (zh) * | 2018-04-25 | 2021-07-23 | 免疫靶向有限公司 | 一种以白介素12为活性成分的融合蛋白型药物前体 |
| EP3861016A2 (en) * | 2018-10-03 | 2021-08-11 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
| CA3117212A1 (en) | 2018-10-23 | 2020-04-30 | Dragonfly Therapeutics, Inc. | Heterodimeric fc-fused proteins |
| CN115916233A (zh) * | 2019-10-03 | 2023-04-04 | Xencor股份有限公司 | 靶向IL-12异源二聚体Fc融合蛋白 |
| MX2022013112A (es) * | 2020-04-22 | 2023-01-16 | Dragonfly Therapeutics Inc | Fórmulacion, regimen de dosificación y proceso de manufactura de proteínas heterodiméricas fusionadas con fc. |
| WO2022125986A1 (en) * | 2020-12-10 | 2022-06-16 | Invenra Inc. | Orthogonal mutations for heterodimerization |
| JP2024539139A (ja) | 2021-10-20 | 2024-10-28 | シンセカイン インコーポレイテッド | ヘテロ二量体ｆｃサイトカインおよびその使用 |
| KR102796245B1 (ko) * | 2022-05-10 | 2025-04-18 | 아주대학교산학협력단 | 인터루킨21 변이체, 이를 포함하는 융합단백질 및 이의 용도 |
| WO2024086739A1 (en) | 2022-10-20 | 2024-04-25 | Synthekine, Inc. | Methods and compositions of il12 muteins and il2 muteins |
| WO2024094755A1 (en) * | 2022-11-02 | 2024-05-10 | Synerkine Pharma B.V. | Engineered immunocytokines, fusion polypeptides, and il10 polypeptides |
| AU2023378481A1 (en) * | 2022-11-10 | 2025-06-19 | Kanglitai Biomedical (Qingdao) Co., Ltd. | Site-specific pegylated heteromeric protein or polypeptide, and preparation method therefor and use thereof |
| WO2024249320A1 (en) * | 2023-05-26 | 2024-12-05 | University Of Florida Research Foundation, Incorporated | In vivo optimization of biologics |
| CN117986386B (zh) * | 2024-02-06 | 2024-11-29 | 康立泰生物医药(青岛)有限公司 | 重组人白细胞介素-35及其制备方法和应用 |
Family Cites Families (82)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| US7951917B1 (en) | 1997-05-02 | 2011-05-31 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| EP1489100B1 (en) | 1997-12-08 | 2016-06-15 | Merck Patent GmbH | Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US7183387B1 (en) | 1999-01-15 | 2007-02-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US6864235B1 (en) | 1999-04-01 | 2005-03-08 | Eva A. Turley | Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans |
| AU2001292943A1 (en) | 2000-09-21 | 2002-04-02 | The Brigham And Women's Hospital, Inc. | Prevention and treatment of streptococcal and staphylococcal infection |
| US8192744B2 (en) | 2002-08-26 | 2012-06-05 | Ibcc Holding As | Drug for treating states related to the inhibition of angiogenesis and/or endothelial cell proliferation |
| EP1752767B1 (en) | 2004-05-20 | 2011-07-13 | Wako Pure Chemical Industries, Ltd. | Method of assaying hyaluronic acid by using hyaluronic acid-binding protein |
| EP1896386B1 (en) | 2005-06-08 | 2012-09-05 | Cangene Corporation | Hyaluronic acid binding peptides enhance host defense against pathogenic bacteria |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2007110205A2 (en) | 2006-03-24 | 2007-10-04 | Merck Patent Gmbh | Engineered heterodimeric protein domains |
| WO2008018519A1 (fr) | 2006-08-08 | 2008-02-14 | Seikagaku Corporation | Procédé de détermination du poids moléculaire d'un acide hyaluronique |
| WO2008089448A2 (en) | 2007-01-19 | 2008-07-24 | Cornell Presearch Foundation, Inc. | Methods and compositions for promoting survival & proliferation of endothelial cells & stimulating angiogenesis |
| DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
| SG189730A1 (en) | 2008-04-02 | 2013-05-31 | Macrogenics Inc | Her2/neu-specific antibodies and methods of using same |
| EP2270145B1 (en) | 2008-04-15 | 2013-01-16 | Wako Pure Chemical Industries, Ltd. | Novel protein capable of binding to hyaluronic acid, and method for measurement of hyaluronic acid using the same |
| SG172354A1 (en) | 2009-01-29 | 2011-07-28 | Medimmune Llc | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
| JP5587975B2 (ja) | 2009-04-07 | 2014-09-10 | ロシュ グリクアート アクチェンゲゼルシャフト | 二重特異的抗−ＥｒｂＢ−３／抗−ｃ−Ｍｅｔ抗体 |
| AU2010285071A1 (en) | 2009-08-17 | 2012-02-02 | Roche Glycart Ag | Targeted immunoconjugates |
| WO2011028952A1 (en) | 2009-09-02 | 2011-03-10 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| JP6040148B2 (ja) | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| CA2796633C (en) | 2010-04-23 | 2020-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
| WO2012025530A1 (en) | 2010-08-24 | 2012-03-01 | F. Hoffmann-La Roche Ag | Bispecific antibodies comprising a disulfide stabilized - fv fragment |
| WO2012032080A1 (en) | 2010-09-07 | 2012-03-15 | F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H | Stabilised human fc |
| WO2012051147A1 (en) | 2010-10-11 | 2012-04-19 | Abbott Laboratories | Processes for purification of proteins |
| MX352929B (es) | 2010-11-05 | 2017-12-13 | Zymeworks Inc | DISEÑO DE ANTICUERPOS HETERODIMÉRICOS ESTABLES CON MUTACIONES EN EL DOMINIO Fc. |
| ES2693232T3 (es) | 2010-11-30 | 2018-12-10 | Chugai Seiyaku Kabushiki Kaisha | Agente terapéutico que induce citotoxicidad |
| US10689447B2 (en) | 2011-02-04 | 2020-06-23 | Genentech, Inc. | Fc variants and methods for their production |
| PE20181077A1 (es) | 2011-02-10 | 2018-07-05 | Roche Glycart Ag | Polipeptidos interleuquina-2-mutantes |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| HRP20170482T1 (hr) | 2011-05-24 | 2017-05-19 | Symic Ip, Llc | Sintetski peptidoglikani koji vežu hijaluronsku kiselinu, dobivanje, i postupci uporabe |
| WO2013012733A1 (en) | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
| PL3351261T3 (pl) | 2011-10-11 | 2021-12-06 | Universität Zürich | Lek złożony zawierający IL-12 i środek do blokowania cząsteczek hamujących komórki T w terapii nowotworów |
| EP2804586A4 (en) | 2012-01-19 | 2016-03-16 | Univ Johns Hopkins | BIOMATERIALS CONTAINING HYALURONIC ACID BINDING PEPTIDES AND BIFUNCTIONAL BIOPOLYMERMOLUCKS FOR HYALURONIC ACIDIC TREATMENT AND TISSUE RENEWAL APPLICATIONS |
| MX360110B (es) | 2012-04-20 | 2018-10-23 | Merus Nv | Metodos y medios para la produccion de moleculas de tipo ig. |
| WO2013163766A1 (en) | 2012-05-04 | 2013-11-07 | Cangene Corporation | ANTIMICROBIAL COMPOSITIONS COMPRISING A HYALURONIC ACID BINDING PEPTIDE AND A β-LACTAM ANTIBIOTIC |
| ES2602030T3 (es) | 2012-08-02 | 2017-02-17 | F. Hoffmann-La Roche Ag | Método para producir RFc solubles como fusión de Fc con la región Fc de inmunoglobulina inerte y usos de los mismos |
| BR112015002091A2 (pt) | 2012-08-02 | 2017-12-12 | Hoffmann La Roche | método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição |
| MY175687A (en) | 2012-08-07 | 2020-07-06 | Roche Glycart Ag | Composition comprising two antibodies engineered to have reduced and increased effector function |
| WO2014054804A1 (ja) | 2012-10-05 | 2014-04-10 | 協和発酵キリン株式会社 | ヘテロダイマータンパク質組成物 |
| EA032681B1 (ru) | 2012-11-27 | 2019-07-31 | Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн | ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ |
| LT2970422T (lt) | 2013-03-15 | 2018-06-25 | F. Hoffmann-La Roche Ag | Il-22 polipeptidai ir il-22 su fc sulieti baltymai bei panaudojimo būdai |
| US10544187B2 (en) * | 2013-03-15 | 2020-01-28 | Xencor, Inc. | Targeting regulatory T cells with heterodimeric proteins |
| US10047167B2 (en) | 2013-03-15 | 2018-08-14 | Eli Lilly And Company | Methods for producing fabs and bi-specific antibodies |
| US20140302037A1 (en) | 2013-03-15 | 2014-10-09 | Amgen Inc. | BISPECIFIC-Fc MOLECULES |
| JP6618893B2 (ja) | 2013-04-29 | 2019-12-11 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｆｃ受容体結合が変更された非対称抗体および使用方法 |
| AR096891A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
| UA117289C2 (uk) | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| CA2943707A1 (en) | 2014-05-06 | 2015-11-12 | Genentech, Inc. | Production of heteromultimeric proteins using mammalian cells |
| KR101721295B1 (ko) | 2014-06-11 | 2017-04-10 | 주식회사 엘지화학 | 염화비닐계 수지의 제조방법 |
| JP6822849B2 (ja) | 2014-06-27 | 2021-01-27 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 多重特異的ＮＫｐ４６結合タンパク質 |
| EP3842453A1 (en) | 2014-11-06 | 2021-06-30 | F. Hoffmann-La Roche AG | Fc-region variants with modified fcrn- and protein a-binding properties |
| EP3215528B1 (en) | 2014-11-06 | 2019-08-07 | F.Hoffmann-La Roche Ag | Fc-region variants with modified fcrn-binding and methods of use |
| CN104628870A (zh) * | 2015-02-04 | 2015-05-20 | 中国药科大学 | 一种人IL12Rβ1-CHR蛋白及其Fc融合蛋白 |
| RS62151B1 (sr) | 2015-08-07 | 2021-08-31 | Alx Oncology Inc | Konstrukti koji sadrže sirp-alfa domen ili njegovu varijantu |
| KR102716215B1 (ko) | 2015-10-06 | 2024-10-10 | 리젠츠 오브 더 유니버시티 오브 미네소타 | 치료 화합물 및 방법 |
| KR101851380B1 (ko) | 2015-10-12 | 2018-04-23 | 아주대학교산학협력단 | 효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍 |
| EP3478717B1 (en) | 2016-07-04 | 2022-01-05 | F. Hoffmann-La Roche AG | Novel antibody format |
| WO2018030806A1 (ko) | 2016-08-10 | 2018-02-15 | 아주대학교산학협력단 | 항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물 |
| KR102050463B1 (ko) | 2016-08-10 | 2019-11-29 | 아주대학교산학협력단 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 사이토카인 (heterodimeric Fc-fused cytokine) 및 이를 포함하는 약제학적 조성물 |
| KR101928981B1 (ko) | 2016-09-02 | 2018-12-13 | 고려대학교 산학협력단 | 항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물 |
| PE20240950A1 (es) | 2016-10-14 | 2024-05-06 | Xencor Inc | PROTEINAS DE FUSION FC HETERODIMERICAS IL 15/IL 15R(alfa) |
| KR20190120782A (ko) | 2017-02-20 | 2019-10-24 | 드래곤플라이 쎄라퓨틱스, 인크. | Her2, nkg2d 및 cd16에 결합하는 단백질 |
| CA3056837A1 (en) | 2017-03-27 | 2018-10-04 | F. Hoffmann-La Roche Ag | Improved antigen binding receptors |
| CA3062519A1 (en) | 2017-05-11 | 2018-11-15 | Emd Millipore Corporation | Method of maintaining narrow residence time distributions in continuous flow systems using solid material packet interfaces |
| SG11201909949XA (en) | 2017-05-24 | 2019-11-28 | Pandion Therapeutics Inc | Targeted immunotolerance |
| MX2019015304A (es) | 2017-06-21 | 2020-02-17 | Cephalon Inc | Amortiguador de lavado para cromatografia de intercambio cationico. |
| JP2019014449A (ja) | 2017-07-10 | 2019-01-31 | トヨタ自動車株式会社 | 車両用動力伝達装置 |
| SG10202102502VA (en) | 2017-09-07 | 2021-04-29 | Dragonfly Therapeutics Inc | Proteins binding nkg2d, cd16 and a tumor-associated antigen |
| US11572395B2 (en) | 2017-09-21 | 2023-02-07 | Merck Patent Gmbh | Fusion protein comprising an FGF-18 moiety |
| CA3075693A1 (en) | 2017-09-22 | 2019-03-28 | WuXi Biologics Ireland Limited | Bispecific polypeptide complexes |
| KR20200067197A (ko) | 2017-10-20 | 2020-06-11 | 에프. 호프만-라 로슈 아게 | 단일특이적 항체로부터 다중특이적 항체의 생성 방법 |
| KR20210042326A (ko) | 2018-07-11 | 2021-04-19 | 모멘타 파머슈티컬스 인코포레이티드 | 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법 |
| EP3861016A2 (en) | 2018-10-03 | 2021-08-11 | Xencor, Inc. | Il-12 heterodimeric fc-fusion proteins |
| CA3117212A1 (en) | 2018-10-23 | 2020-04-30 | Dragonfly Therapeutics, Inc. | Heterodimeric fc-fused proteins |
-
2017
- 2017-08-10 KR KR1020170101594A patent/KR102050463B1/ko active Active
- 2017-08-10 EP EP17839824.4A patent/EP3511340B1/en active Active
- 2017-08-10 BR BR112019002394-1A patent/BR112019002394B1/pt active IP Right Grant
- 2017-08-10 EP EP24194198.8A patent/EP4470552A3/en active Pending
- 2017-08-10 JP JP2019506697A patent/JP6993403B2/ja active Active
- 2017-08-10 MX MX2019001651A patent/MX386014B/es unknown
- 2017-08-10 DK DK17839824.4T patent/DK3511340T3/da active
- 2017-08-10 SG SG11201901071TA patent/SG11201901071TA/en unknown
- 2017-08-10 CA CA3033475A patent/CA3033475A1/en active Pending
- 2017-08-10 ES ES17839824T patent/ES3000558T3/es active Active
- 2017-08-10 CN CN201780062851.0A patent/CN110267977A/zh active Pending
- 2017-08-10 US US16/323,839 patent/US10696722B2/en active Active
- 2017-08-10 AU AU2017310163A patent/AU2017310163B2/en active Active
-
2019
- 2019-02-06 IL IL264692A patent/IL264692B2/en unknown
- 2019-02-06 ZA ZA2019/00772A patent/ZA201900772B/en unknown
- 2019-02-08 MX MX2021010809A patent/MX2021010809A/es unknown
- 2019-11-25 KR KR1020190152270A patent/KR102416411B1/ko active Active
-
2020
- 2020-05-28 US US16/886,177 patent/US11078249B2/en active Active
- 2020-05-28 US US16/886,184 patent/US11692019B2/en active Active
-
2021
- 2021-03-03 JP JP2021033816A patent/JP7111855B2/ja active Active
- 2021-11-26 AU AU2021273642A patent/AU2021273642B2/en active Active
-
2022
- 2022-06-29 KR KR1020220079686A patent/KR102607285B1/ko active Active
- 2022-07-21 JP JP2022116329A patent/JP7488854B2/ja active Active
-
2023
- 2023-05-24 US US18/323,124 patent/US12358964B2/en active Active
- 2023-11-23 KR KR1020230164332A patent/KR102652247B1/ko active Active